Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- DAIICHI SANKYO CO LTD
- Publication Date
- 2019-11-19
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to a therapeutic agent and treatment method for EGFR-TKI resistant non-small cell lung cancer, which is characterized in that the anti-HER3 antibody-drug conjugate is administered. Background technique
[0002] In the treatment of EGFR tyrosine kinase inhibitor (EGFR-TKI), which is effective for epidermal growth factor receptor (Epidermal Growth Factor Receptor; EGFR) gene mutation-positive non-small cell lung cancer, in most cases, continuous treatment In the course of treatment, the resistance of the target cancer to the inhibitor is enhanced, and the disease is exacerbated as a result. Known: Cancers resistant to Gefitinib and Erlotinib as first-generation EGFR-TKIs, and afatinib as second-generation EGFR-TKIs About half of them have the T790M mutation in the EGFR gene. Osimertinib, which is a third-generation EGFR-TKI, is known as an effective drug against non-small cell lung cancer confirmed to be EGFR T790M mutatio...